Study design and participants
chronic musculoskeletal diseases, ’, decompensated heart failure, MetS, metabolic syndrome, TG, diabetes
METABOLIC SYNDROME, DECOMPENSATED HEART FAILURE, HIGH BLOOD PRESSURE, DIABETES
This study is a clinical trial (approved by the Iranian Registry of Clinical Trials, IRCT20221120056548N1 on 23 November 2022, retrospectively). It was conducted among women with MetS who were referred to the diabetes clinic of Imam Hossein Malayer Hospital due to diabetes between September and January 2021. The volunteer participants were briefed on the purpose of the study. They also filled in a written informed consent form. Approval was received from the Research Ethics Committee of Bu-Ali Sina University in Hamadan, Iran (IR.BASU.REC.1400.046), as the study observed the guidelines of the Declaration of Helsinki. A woman is classified as having metabolic syndrome depending on whether she presents with at least three out of five abnormal attributes as defined by the IDF standards (2006): these include (i) a waist measurement larger than or equal to 80 centimeters specifically for women; (ii) high blood pressure reaching above 130/85 mmHg; (iii) a fasting blood sugar (FBS) count higher than or equal to 100 mg/dL; (iv) elevated Triglyceride (TG) amounts of more than or equal to 150 mg/dL; and finally, (v) HDL- cholesterol < 50 mg/dL for women [The inclusion criteria included inactive postmenopausal women with an age range of 45–65 years who had no history of regular sports activity in the past year, and at least one year had passed since their last menstrual period. They also did not have any chronic musculoskeletal diseases and were non-smokers.Exclusion criteria included: non-compliance with the study exercise protocol, any change in the patient’s routine program based on the physician’s opinion, decompensated heart failure, and the use of certain drugs or supplements. The individuals’ participation in the study was not disqualified due to their use of medications, as no alterations were made in terms of drug type or dosage. The subjects were also advised not to change their usual diet.The G-Power software determined the sample size based on the previous results obtained for SIRT1 measured in humans [
Flow diagram of study